Drugs / PD-L1 Long(19-27)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04051307 | Jul 2019 → Jul 2022 | acquired polycythemia vera, essential thrombocythemia | Inge Marie Svane | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PD-L1 Long(19-27) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04051307 ↗ |
| Modality | Peptide | “dual vaccinations of ARG1- derived and PD-L1-derived peptides, combined with Montanide ISA-51 as adjuvant” PMID 36911725 ↗ Feb 2023 |